½ÃÀ庸°í¼­
»óǰÄÚµå
1596211

¼¼°èÀÇ Èí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå : ºÎ¹®º° ¿¹Ãø(2025-2030³â)

Resorbable Vascular Scaffold Market by Material Type (Metal Based BVS, Polymer Based BVS), Application (Coronary Artery Stents, Peripheral Artery Stents), End User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 181 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Èí¼ö¼º Ç÷°ü ½ºÄ³Æúµå(RVS, Resorbable Vascular Scaffold) ½ÃÀåÀº 2023³â 5¾ï 712¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 5¾ï 7,657¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, CAGR 13.78%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 12¾ï 5,252¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Èí¼ö¼º Ç÷°ü ½ºÄ³Æúµå(RVS)´Â Ç÷°ü¿¡ ÀϽÃÀûÀÎ ÁöÁö·ÂÀ» Á¦°øÇÏ¿© °ü»óµ¿¸Æ ÁúȯÀ» Ä¡·áÇϱâ À§ÇÑ ½ÉÀå °³ÀÔ¿¡ ÁÖ·Î »ç¿ëµÇ´Â Çõ½ÅÀûÀÎ »ý¹° Èí¼ö¼º ½ºÅÙÆ®ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Çʿ伺Àº Èı⠽ºÅÙÆ® Ç÷ÀüÁõ°ú °°Àº ÀüÅëÀûÀÎ ±Ý¼Ó ½ºÅÙÆ®¿Í °ü·ÃµÈ ÇÕº´ÁõÀ» ÁÙÀÌ´Â µ¿½Ã¿¡ ½ºÄ³Æúµå°¡ ¿ëÇØµÇ¸é µ¿¸ÆÀÌ ÀÚ¿¬½º·¯¿î ¿òÁ÷ÀÓ°ú ±â´ÉÀ» ȸº¹ÇÒ ¼ö ÀÖ´Â ÀáÀç·Â¿¡¼­ ºñ·ÔµË´Ï´Ù. Àû¿ë Ãø¸é¿¡¼­ RVS´Â Ç÷°ü ¼ºÇü¼ú¿¡¼­ ÁßÃßÀûÀÎ ¿ªÇÒÀ» Çϸç, ÃÖÁ¾ »ç¿ë ¹üÀ§´Â ÁÖ·Î º´¿ø, ½ÉÀå ¼¾ÅÍ, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ¿¡ °ÉÃÄ ÀÖ½À´Ï´Ù. RVS ½ÃÀåÀº ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡, »ýºÐÇØ¼º Àç·áÀÇ ¹ßÀü, ÃÖ¼Ò Ä§½ÀÀû ½Ã¼ú¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡·Î ÀÎÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº ºñ¿ë, ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç, ±Ý¼Ó ½ºÅÙÆ®¿¡ ºñÇØ Á¦ÇÑµÈ Àå±â ÀÓ»ó µ¥ÀÌÅÍ µî Áß¿äÇÑ °úÁ¦°¡ ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ±âȸ´Â ÀÇ·á ÀÎÇÁ¶ó°¡ ºü¸£°Ô °³¼±µÇ°í ÷´Ü ÀÇ·á ±â¼ú¿¡ ´ëÇÑ ¼ö¿ëÀÌ Áõ°¡ÇÏ´Â ½ÅÈï ½ÃÀå¿¡ ÀÖ½À´Ï´Ù. ÀÇ·á ¿¬±¸ ±â°ü°úÀÇ Àü·«Àû Çù·ÂÀº Çõ½ÅÀ» ÃËÁøÇÒ ¼ö ÀÖÀ¸¸ç, ƯÈ÷ RVSÀÇ È¿´É ¹× ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀ» Çâ»ó½ÃŰ´Â µ¥ ÀÖ¾î ´õ¿í ±×·¸½À´Ï´Ù. ±â¾÷Àº ´Ù¾çÇÑ È¯ÀÚ ¿ä±¸¸¦ ÃæÁ·Çϱâ À§ÇØ ºÐÇØ ŸÀÓ¶óÀÎÀÌ °³¼±µÇ°í ±â°èÀû Ư¼ºÀÌ Çâ»óµÈ ½ºÄ³Æúµå¸¦ °³¹ßÇÏ´Â µ¥ ÁýÁßÇØ¾ß ÇÕ´Ï´Ù. ¶ÇÇÑ °³ÀÎÈ­¸¦ À§ÇØ Çõ½ÅÀ» ÁÖµµÇÏ¿© °³º° ÇØºÎÇÐÀû Ư¼º°ú Áúº´ ¼¼ºÎ »çÇ׿¡ ¸Â´Â ½ºÄ³Æúµå¸¦ »ý»êÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀå Âü¿©ÀÚµéÀº Àå±âÀûÀÎ ¾ÈÀü¼º ¹× È¿°ú ÁÖÀåÀ» ÀÔÁõÇϱâ À§ÇØ Æ÷°ýÀûÀÎ ÀÓ»ó ½ÃÇè¿¡ ÅõÀÚÇÏ¿© ±ÔÁ¦ ±â°ü°ú ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¸¦ ¸ðµÎ ÃæÁ·ÇÏ´Â °ÍÀÌ ÁÁ½À´Ï´Ù. Àü¹ÝÀûÀ¸·Î RVS ½ÃÀåÀº ½ÉÀå Ä¡·á ºÐ¾ß¿¡¼­ Çõ½ÅÀûÀÎ ÀáÀç·ÂÀ¸·Î À¯¸ÁÇÏÁö¸¸, ÇöÀçÀÇ ÇѰ踦 ±Øº¹ÇÏ°í ±Þ¼ºÀåÇÏ´Â ±âȸ¸¦ Ȱ¿ëÇϱâ À§ÇØ ±ÔÁ¦ ȯ°æ, ºñ¿ë °ü¸® ¹× ±â¼ú °³¼±À» ÅëÇÑ Å½»ö¿¡ ¼¼½ÉÇÑ ³ë·ÂÀÌ ÇÊ¿äÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ¿¬µµ(2023³â) 5¾ï712¸¸ ´Þ·¯
ÃßÁ¤¿¬µµ(2024³â) 5¾ï 7,657¸¸ ´Þ·¯
¿¹Ãø¿¬µµ(2030³â) 12¾ï 5,252¸¸ ´Þ·¯
CAGR(%) 13.78%

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â Èí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀåÀÇ ÁÖ¿ä ÀλçÀÌÆ® °ø°³

Èí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. °áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ» »Ó¸¸ ¾Æ´Ï¶ó ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ³ë³â Àα¸¿¡¼­ CAD ¹× PADÀÇ À§Çè Áõ°¡
    • ÀÓ»ó½ÃÇè ¹× °³¹ß ÆÄÀÌÇÁ¶óÀÎÀÇ ¼ö
    • ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ´ëü¹ýÀÇ Á¸Àç
  • ½ÃÀå ±âȸ
    • ¿Ü°ú ¼ö¼úÀÇ ¿¬±¸ °³¹ß¿¡ ´ëÇÑ ÀÚ±Ý Á¦°ø Áõ°¡
    • Ç÷°ü ¼ºÇü¼ú¿¡¼­ ¾à¹° ¿ëÃâ ÀåÄ¡¿¡ °æ»ç
  • ½ÃÀå °úÁ¦
    • Á¦Ç° ¸®ÄÝ

Porter's Five Forces : Èí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ºñÁî´Ï½º Á¶Á÷ÀÌ °æÀïÀû À§Ä¡¸¦ Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ý·ÐÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ÈûÀÇ ¿ªÇÐ °ü°è¸¦ Æò°¡ÇÏ°í »õ·Î¿î º¥Ã³ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °­Á¡À» Ȱ¿ëÇÏ°í ¾àÁ¡À» ÇØ°áÇϸç ÀáÀçÀûÀÎ ¹®Á¦¸¦ ¹æÁöÇÏ¿© º¸´Ù ź·ÂÀûÀÎ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Èí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå¿¡¼­ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Èí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇϴµ¥ À־ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÏ¸é ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. À» ¿¹ÃøÇÏ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡µÇ¾î ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : Èí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

Èí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÇ Æ÷Áö¼Å´×À» ¹àÇô À̸¦ ÅëÇØ ½ÃÀåÀÇ ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í, º¥´õ´Â °æÀïÀÌ °ÝÈ­ÇÏ´Â °¡¿îµ¥ ÀÚ½ÅÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» Çϱâ À§ÇØ ÇÊ¿äÇϸç, Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : Èí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Èí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡Çϱâ À§ÇÑ Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î º¥´õ¸¦ Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. 4°³ÀÇ »çºÐ¸éÀº °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© »ç¿ëÀÚ°¡ Àü·«Àû ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ : Èí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æÀ» ±×¸®±â

Èí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ±Û·Î¹ú ½ÃÀå ÀÔÁö °­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» ÀÌ·ç±âÀ§ÇÑ ½Ã½ºÅÛÀ» ±¸Ãà ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·ÂÀ» Æò°¡ÇÕ´Ï´Ù.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ÇâÈÄ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ ¹× ±ÔÁ¦ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø ¹× Àü·«Àû ±âȸ´Â?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ³ëÀÎ Àα¸¿¡¼­ CAD ¹× PADÀÇ À§Çè Áõ°¡
      • ÆÄÀÌÇÁ¶óÀÎ ³»ÀÇ ÀÓ»ó½ÃÇè ¹× °³¹ßÀÇ ¼ö
      • ½ÉÇ÷°üÁúȯÀÇ ÀÌȯÀ² Áõ°¡
    • ¾ïÁ¦¿äÀÎ
      • ´ëü ¼ö´ÜÀÇ Á¸Àç
    • ±âȸ
      • ¿Ü°ú ¼ö¼úÀÇ ¿¬±¸ °³¹ß¿¡ ´ëÇÑ ÀÚ±Ý Á¦°ø Áõ°¡
      • Ç÷°ü ¼ºÇü¼ú¿¡¼­ ¾à¹° ¿ëÃâ ÀåÄ¡¿¡ ´ëÇÑ °æÇâ
    • °úÁ¦
      • Á¦Ç° ¸®ÄÝ
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦Àû
    • »çȸÀû
    • ±â¼úÀû
    • ¹ýÀû
    • ȯ°æÀû

Á¦6Àå Èí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå : ¼ÒÀç À¯Çüº°

  • ±Ý¼Ó ±â¹Ý BVS
  • Æú¸®¸Ó ±â¹Ý BVS

Á¦7Àå Èí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå : ¿ëµµº°

  • °ü»óµ¿¸Æ ½ºÅÙÆ®
  • ¸»ÃÊ µ¿¸Æ ½ºÅÙÆ®

Á¦8Àå Èí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • ½ÉÀå¼¾ÅÍ
  • º´¿ø

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ Èí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾Æ ÅÂÆò¾çÀÇ Èí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Èí¼ö¼º Ç÷°ü ½ºÄ³Æúµå ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼® ¹× Ãßõ

±â¾÷ ¸ñ·Ï

  • Abbott Laboratories
  • B. Braun Medical Inc.
  • Biotronik SE&Co. KG
  • Cardionovum GmbH
  • Elixir Medical Corporation
  • Kyoto Medical Planning Co., Ltd.
  • Lepu Medical Technology(Beijing) Co.,Ltd.
  • Medtronic PLC
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • OrbusNeich Medical Company Limited
  • Reva Medical, Inc.
  • Terumo Corporation
  • Translumina
  • Wego Healthcare(Shenzhen) Co., Ltd.
LYJ

The Resorbable Vascular Scaffold Market was valued at USD 507.12 million in 2023, expected to reach USD 576.57 million in 2024, and is projected to grow at a CAGR of 13.78%, to USD 1,252.52 million by 2030.

Resorbable vascular scaffolds (RVS) are innovative bioresorbable stents used primarily in cardiac interventions to treat coronary artery disease by providing temporary support to the blood vessel. The necessity arises from their potential to reduce complications associated with traditional metal stents, such as late stent thrombosis, while allowing the artery to restore its natural movement and function once the scaffold dissolves. In terms of application, RVS are pivotal in angioplasty procedures, and their end-use scope primarily spans across hospitals, cardiac centers, and ambulatory surgical centers. The market for RVS is driven by the increasing prevalence of cardiovascular disorders, advancements in biodegradable materials, and a growing preference for minimally invasive procedures. However, significant challenges, including high costs, stringent regulatory requirements, and limited long-term clinical data compared to metallic stents, could inhibit growth. Opportunities lie in emerging markets where healthcare infrastructure is rapidly improving, and there's an increasing acceptance of advanced medical technologies. Strategic collaborations with medical research institutions could expedite innovation, particularly in enhancing the efficacy and safety profiles of RVS. Companies should focus on developing scaffolds with improved degradation timelines and enhanced mechanical properties to meet diverse patient needs. Innovation can also be steered towards personalization, producing scaffolds that cater to individual anatomical peculiarities and disease specifics. Market players are advised to invest in comprehensive clinical trials to substantiate long-term safety and effectiveness claims, thereby satisfying both regulatory bodies and healthcare providers. Overall, the RVS market is promising due to its transformative potential in cardiac care; however, it demands meticulous effort in navigation through regulatory landscapes, cost management, and technological enhancements to surmount current limitations and capitalize on burgeoning opportunities.

KEY MARKET STATISTICS
Base Year [2023] USD 507.12 million
Estimated Year [2024] USD 576.57 million
Forecast Year [2030] USD 1,252.52 million
CAGR (%) 13.78%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Resorbable Vascular Scaffold Market

The Resorbable Vascular Scaffold Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing Risk of CAD and PAD in the geriatric population
    • Number of clinical trials and development in pipeline
    • Increasing prevalence of cardiovascular diseases
  • Market Restraints
    • Presence of alternative methods
  • Market Opportunities
    • Growing funding for R&D of surgical procedures
    • Inclination towards drug-eluting devices for angioplasty
  • Market Challenges
    • Product recall

Porter's Five Forces: A Strategic Tool for Navigating the Resorbable Vascular Scaffold Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Resorbable Vascular Scaffold Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Resorbable Vascular Scaffold Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Resorbable Vascular Scaffold Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Resorbable Vascular Scaffold Market

A detailed market share analysis in the Resorbable Vascular Scaffold Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Resorbable Vascular Scaffold Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Resorbable Vascular Scaffold Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Resorbable Vascular Scaffold Market

A strategic analysis of the Resorbable Vascular Scaffold Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Resorbable Vascular Scaffold Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, B. Braun Medical Inc., Biotronik SE & Co. KG, Cardionovum GmbH, Elixir Medical Corporation, Kyoto Medical Planning Co., Ltd., Lepu Medical Technology(Beijing)Co.,Ltd., Medtronic PLC, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, OrbusNeich Medical Company Limited, Reva Medical, Inc., Terumo Corporation, Translumina, and Wego Healthcare (Shenzhen) Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Resorbable Vascular Scaffold Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Material Type, market is studied across Metal Based BVS and Polymer Based BVS.
  • Based on Application, market is studied across Coronary Artery Stents and Peripheral Artery Stents.
  • Based on End User, market is studied across Ambulatory Surgical Centers, Cardiac Centers, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing Risk of CAD and PAD in the geriatric population
      • 5.1.1.2. Number of clinical trials and development in pipeline
      • 5.1.1.3. Increasing prevalence of cardiovascular diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Presence of alternative methods
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing funding for R&D of surgical procedures
      • 5.1.3.2. Inclination towards drug-eluting devices for angioplasty
    • 5.1.4. Challenges
      • 5.1.4.1. Product recall
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Resorbable Vascular Scaffold Market, by Material Type

  • 6.1. Introduction
  • 6.2. Metal Based BVS
  • 6.3. Polymer Based BVS

7. Resorbable Vascular Scaffold Market, by Application

  • 7.1. Introduction
  • 7.2. Coronary Artery Stents
  • 7.3. Peripheral Artery Stents

8. Resorbable Vascular Scaffold Market, by End User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Cardiac Centers
  • 8.4. Hospitals

9. Americas Resorbable Vascular Scaffold Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Resorbable Vascular Scaffold Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Resorbable Vascular Scaffold Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. B. Braun Medical Inc.
  • 3. Biotronik SE & Co. KG
  • 4. Cardionovum GmbH
  • 5. Elixir Medical Corporation
  • 6. Kyoto Medical Planning Co., Ltd.
  • 7. Lepu Medical Technology(Beijing)Co.,Ltd.
  • 8. Medtronic PLC
  • 9. Meril Life Sciences Pvt. Ltd.
  • 10. MicroPort Scientific Corporation
  • 11. OrbusNeich Medical Company Limited
  • 12. Reva Medical, Inc.
  • 13. Terumo Corporation
  • 14. Translumina
  • 15. Wego Healthcare (Shenzhen) Co., Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦